Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson's disease: a systematic review and meta-analysis

Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson's disease: a systematic review and meta-analysis

Background Recent research on Parkinson's disease (PD) therapy has highlighted glucagon-like peptide 1 (GLP-1) agonists as potential therapeutic agents. However, recent randomized controlled trials (RCTs) have shown mixed results regarding the use of this medication.

Saved in:
Bibliographic Details
Main Authors: Luis O. S. Nogueira, Roberto A. S. V. Mazetto, Maria L. R. Defante, Vânio L. J. Antunes, Ocílio Ribeiro Gonçalves, Angela Maria Sandini Corso, Marcus V. Della Coletta, Dayany Leonel Boone, Walderico Silva Machado Filho, Vanderci Borges, Henrique Ballalai Ferraz
Format: Article
Language:English
Published: Thieme Revinter Publicações 2025-04-01
Series:Arquivos de Neuro-Psiquiatria
Subjects:
Glucagon-Like peptide 1
Parkinson Disease
Randomized Controlled Trial
Movement Disorders
Meta-Analysis
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1806824
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Recent research on Parkinson's disease (PD) therapy has highlighted glucagon-like peptide 1 (GLP-1) agonists as potential therapeutic agents. However, recent randomized controlled trials (RCTs) have shown mixed results regarding the use of this medication.
ISSN:0004-282X
1678-4227

Similar Items